CN112585282A - 鉴定乳腺癌状态的方法和试剂盒 - Google Patents
鉴定乳腺癌状态的方法和试剂盒 Download PDFInfo
- Publication number
- CN112585282A CN112585282A CN201880095981.9A CN201880095981A CN112585282A CN 112585282 A CN112585282 A CN 112585282A CN 201880095981 A CN201880095981 A CN 201880095981A CN 112585282 A CN112585282 A CN 112585282A
- Authority
- CN
- China
- Prior art keywords
- seq
- sequence
- sequence shown
- primer pair
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 141
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 141
- 238000000034 method Methods 0.000 title claims abstract description 59
- 230000011987 methylation Effects 0.000 claims abstract description 169
- 238000007069 methylation reaction Methods 0.000 claims abstract description 169
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 155
- 239000000090 biomarker Substances 0.000 claims abstract description 98
- 239000012472 biological sample Substances 0.000 claims abstract description 86
- 101150072950 BRCA1 gene Proteins 0.000 claims abstract description 56
- 102100024185 G1/S-specific cyclin-D2 Human genes 0.000 claims abstract description 55
- 101000980741 Homo sapiens G1/S-specific cyclin-D2 Proteins 0.000 claims abstract description 54
- 102100033909 Retinoic acid receptor beta Human genes 0.000 claims abstract description 52
- 108700020463 BRCA1 Proteins 0.000 claims abstract description 44
- 102000036365 BRCA1 Human genes 0.000 claims abstract description 44
- 101000595669 Homo sapiens Pituitary homeobox 2 Proteins 0.000 claims abstract description 42
- 102100036090 Pituitary homeobox 2 Human genes 0.000 claims abstract description 42
- 102100030943 Glutathione S-transferase P Human genes 0.000 claims abstract description 38
- 101000884770 Homo sapiens Cystatin-M Proteins 0.000 claims abstract description 38
- 101001010139 Homo sapiens Glutathione S-transferase P Proteins 0.000 claims abstract description 38
- 101000912191 Homo sapiens Cystatin-B Proteins 0.000 claims abstract description 37
- -1 RASSF1A Proteins 0.000 claims abstract description 28
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 claims abstract description 16
- 101001132698 Homo sapiens Retinoic acid receptor beta Proteins 0.000 claims abstract 14
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims abstract 12
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims abstract 12
- 102100026891 Cystatin-B Human genes 0.000 claims abstract 8
- 101001033026 Homo sapiens Platelet glycoprotein V Proteins 0.000 claims abstract 8
- 102100038411 Platelet glycoprotein V Human genes 0.000 claims abstract 8
- 230000000903 blocking effect Effects 0.000 claims description 133
- 239000000523 sample Substances 0.000 claims description 123
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 114
- 229920001184 polypeptide Polymers 0.000 claims description 112
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 112
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 96
- 238000001514 detection method Methods 0.000 claims description 94
- 238000006243 chemical reaction Methods 0.000 claims description 75
- 238000012408 PCR amplification Methods 0.000 claims description 74
- 239000012634 fragment Substances 0.000 claims description 69
- 108020004414 DNA Proteins 0.000 claims description 63
- 206010028980 Neoplasm Diseases 0.000 claims description 43
- 238000011282 treatment Methods 0.000 claims description 36
- 201000011510 cancer Diseases 0.000 claims description 33
- 150000007523 nucleic acids Chemical class 0.000 claims description 23
- 101000652324 Homo sapiens Transcription factor SOX-17 Proteins 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- 238000007477 logistic regression Methods 0.000 claims description 18
- 239000003153 chemical reaction reagent Substances 0.000 claims description 17
- 230000003321 amplification Effects 0.000 claims description 16
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 16
- 108700001666 APC Genes Proteins 0.000 claims description 13
- 108700040618 BRCA1 Genes Proteins 0.000 claims description 13
- 101100310647 Homo sapiens SOX17 gene Proteins 0.000 claims description 13
- 101150007417 SOX17 gene Proteins 0.000 claims description 13
- 102100030243 Transcription factor SOX-17 Human genes 0.000 claims description 13
- 210000002381 plasma Anatomy 0.000 claims description 13
- 101150023402 CST6 gene Proteins 0.000 claims description 12
- 101150079049 Ccnd2 gene Proteins 0.000 claims description 12
- 101150115318 GP5 gene Proteins 0.000 claims description 12
- 101150031628 PITX2 gene Proteins 0.000 claims description 12
- 101150010097 RARB gene Proteins 0.000 claims description 12
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 12
- 101150008380 gstp1 gene Proteins 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 238000007400 DNA extraction Methods 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 9
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical group [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 claims description 7
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims description 7
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 5
- 238000001574 biopsy Methods 0.000 claims description 5
- 210000000481 breast Anatomy 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 claims description 5
- 238000005259 measurement Methods 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 101150087690 ACTB gene Proteins 0.000 claims description 4
- 206010006199 Breast cancer stage I Diseases 0.000 claims description 4
- 206010006200 Breast cancer stage II Diseases 0.000 claims description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 210000002751 lymph Anatomy 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 238000010791 quenching Methods 0.000 claims description 4
- 230000000171 quenching effect Effects 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 3
- 238000011191 terminal modification Methods 0.000 claims description 3
- 238000010923 batch production Methods 0.000 claims 1
- 108091008761 retinoic acid receptors β Proteins 0.000 description 38
- 101000712958 Homo sapiens Ras association domain-containing protein 1 Proteins 0.000 description 37
- 102100033243 Ras association domain-containing protein 1 Human genes 0.000 description 31
- 102100038381 Cystatin-M Human genes 0.000 description 30
- 239000000243 solution Substances 0.000 description 23
- 239000011324 bead Substances 0.000 description 20
- 239000003550 marker Substances 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 239000011534 wash buffer Substances 0.000 description 12
- 239000007853 buffer solution Substances 0.000 description 11
- 239000006174 pH buffer Substances 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 11
- 239000006148 magnetic separator Substances 0.000 description 10
- 238000009826 distribution Methods 0.000 description 9
- 229940122426 Nuclease inhibitor Drugs 0.000 description 8
- 238000004140 cleaning Methods 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 239000003398 denaturant Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000007067 DNA methylation Effects 0.000 description 6
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- 239000012149 elution buffer Substances 0.000 description 6
- 238000003908 quality control method Methods 0.000 description 6
- 239000012148 binding buffer Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000012139 lysis buffer Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 4
- 238000013399 early diagnosis Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000010414 supernatant solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091029523 CpG island Proteins 0.000 description 3
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 208000011803 breast fibrocystic disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- AOSFMYBATFLTAQ-UHFFFAOYSA-N 1-amino-3-(benzimidazol-1-yl)propan-2-ol Chemical compound C1=CC=C2N(CC(O)CN)C=NC2=C1 AOSFMYBATFLTAQ-UHFFFAOYSA-N 0.000 description 1
- BRRSNXCXLSVPFC-UHFFFAOYSA-N 2,3,4-Trihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1O BRRSNXCXLSVPFC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UDGUGZTYGWUUSG-UHFFFAOYSA-N 4-[4-[[2,5-dimethoxy-4-[(4-nitrophenyl)diazenyl]phenyl]diazenyl]-n-methylanilino]butanoic acid Chemical compound COC=1C=C(N=NC=2C=CC(=CC=2)N(C)CCCC(O)=O)C(OC)=CC=1N=NC1=CC=C([N+]([O-])=O)C=C1 UDGUGZTYGWUUSG-UHFFFAOYSA-N 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010058544 Cyclin D2 Proteins 0.000 description 1
- 230000026641 DNA hypermethylation Effects 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- PQUCIEFHOVEZAU-UHFFFAOYSA-N Diammonium sulfite Chemical compound [NH4+].[NH4+].[O-]S([O-])=O PQUCIEFHOVEZAU-UHFFFAOYSA-N 0.000 description 1
- 208000007358 Galactocele Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000009184 Neoplasms by Histologic Type Diseases 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 101710176387 Transcription factor SOX-17 Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013398 bayesian method Methods 0.000 description 1
- 238000001369 bisulfite sequencing Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 238000007847 digital PCR Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000014200 hypermethylation of CpG island Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000010758 lactocele Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000009607 mammography Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000007855 methylation-specific PCR Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 150000005430 trihydroxybenzoic acid derivatives Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
一种在受试者中鉴定乳腺癌状态的方法，包括：1)从所述受试者采集生物样品；2)检测所述生物样品中生物标志物基因的甲基化水平，其中所述生物标志物基因选自如下基因的一种或多种：APC、BRCA1、CCND2、CST6、GP5、GSTP1、PITX2、RARB、RASSF1A和SOX17；以及3)将步骤2)检测的甲基化水平与群体中相应生物标志物基因的正常甲基化水平进行比较，以确定所述受试者中的乳腺癌状态。还提供了用于鉴定受试者中乳腺癌状态的试剂盒。
Description
PCT国内申请，说明书已公开。
Claims (38)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/097296 WO2020019268A1 (zh) | 2018-07-26 | 2018-07-26 | 鉴定乳腺癌状态的方法和试剂盒 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112585282A true CN112585282A (zh) | 2021-03-30 |
Family
ID=69180714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880095981.9A Pending CN112585282A (zh) | 2018-07-26 | 2018-07-26 | 鉴定乳腺癌状态的方法和试剂盒 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20210324479A1 (zh) |
| EP (1) | EP3828290A4 (zh) |
| CN (1) | CN112585282A (zh) |
| WO (1) | WO2020019268A1 (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005040421A2 (en) * | 2003-10-17 | 2005-05-06 | Martin Widschwendter | Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues |
| WO2006008128A2 (en) * | 2004-07-18 | 2006-01-26 | Epigenomics Ag | Epigenetic methods and nucleic acids for the detection of breast cell proliferative disorders |
| WO2016168174A1 (en) * | 2015-04-13 | 2016-10-20 | The Translational Genomics Research Institute | Predicting the occurrence of metastatic cancer using epigenomic biomarkers and non-invasive methodologies |
| CN107164524A (zh) * | 2017-06-27 | 2017-09-15 | 深圳市优圣康生物科技有限公司 | 用于基因甲基化检测的引物和探针、采样方法、试剂盒 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5541308A (en) * | 1986-11-24 | 1996-07-30 | Gen-Probe Incorporated | Nucleic acid probes for detection and/or quantitation of non-viral organisms |
| KR100470221B1 (ko) * | 2002-02-20 | 2005-02-05 | 굿젠 주식회사 | 유전자 프로모터 ＣｐＧ 아일랜드의 메틸화 여부를분석하는 염기서열분석형 올리고뉴클레오타이드칩, 이의제조방법 및 이를 이용한 암 검색방법 |
| WO2008066878A2 (en) * | 2006-11-29 | 2008-06-05 | University Of Vermont And State Agricultural College | Methods and products for diagnosing cancer |
| US20070141582A1 (en) * | 2005-12-15 | 2007-06-21 | Weiwei Li | Method and kit for detection of early cancer or pre-cancer using blood and body fluids |
| WO2009108917A2 (en) * | 2008-02-29 | 2009-09-03 | Oncomethylome Sciences, S.A. | Markers for improved detection of breast cancer |
| CN107922941A (zh) * | 2015-06-15 | 2018-04-17 | 塞弗德公司 | 在自动化反应盒中DNA甲基化的整合的纯化和测量以及突变和/或mRNA表达水平的共同测量 |
-
2018
- 2018-07-26 CN CN201880095981.9A patent/CN112585282A/zh active Pending
- 2018-07-26 EP EP18927940.9A patent/EP3828290A4/en active Pending
- 2018-07-26 US US17/263,306 patent/US20210324479A1/en not_active Abandoned
- 2018-07-26 WO PCT/CN2018/097296 patent/WO2020019268A1/zh active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005040421A2 (en) * | 2003-10-17 | 2005-05-06 | Martin Widschwendter | Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues |
| WO2006008128A2 (en) * | 2004-07-18 | 2006-01-26 | Epigenomics Ag | Epigenetic methods and nucleic acids for the detection of breast cell proliferative disorders |
| WO2016168174A1 (en) * | 2015-04-13 | 2016-10-20 | The Translational Genomics Research Institute | Predicting the occurrence of metastatic cancer using epigenomic biomarkers and non-invasive methodologies |
| CN107164524A (zh) * | 2017-06-27 | 2017-09-15 | 深圳市优圣康生物科技有限公司 | 用于基因甲基化检测的引物和探针、采样方法、试剂盒 |
Non-Patent Citations (1)
| Title |
|---|
| 符德元: "乳腺癌相关基因异常甲基化的临床实验研究", 《中国博士学位论文全文数据库医药卫生科技辑》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3828290A4 (en) | 2022-03-23 |
| US20210324479A1 (en) | 2021-10-21 |
| EP3828290A1 (en) | 2021-06-02 |
| WO2020019268A1 (zh) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112567049A (zh) | 鉴定胃癌状态的方法和试剂盒 | |
| CN111630186A (zh) | 鉴定肺癌状态的方法和试剂盒 | |
| CN111630187A (zh) | 鉴定结直肠癌状态的方法和试剂盒 | |
| CN109022567A (zh) | 用于鉴定肺结节和/或肺癌状态的试剂盒及其应用 | |
| CN113249477A (zh) | 结直肠癌早期诊断的方法和试剂盒 | |
| WO2016115354A1 (en) | Methods for cancer diagnosis and prognosis | |
| KR102067607B1 (ko) | Y 염색체 메틸화 사이트의 전립선암 진단 마커로써의 응용 | |
| CN108977544A (zh) | 用于鉴定胃癌和/或胃息肉的试剂盒及其应用 | |
| CN109082467A (zh) | 用于鉴定乳腺癌状态或乳腺癌前病变的试剂盒及其应用 | |
| KR102546357B1 (ko) | 인간 포스포다이에스테라제 4d 변이체 7 발현에 기초한 위험 점수 | |
| EP3368684B1 (en) | Biomarker for breast cancer | |
| CN113186282B (zh) | 鉴定胰腺癌状态的方法和试剂盒 | |
| CN113234821B (zh) | 鉴定食管癌状态的方法和试剂盒 | |
| US20190360061A1 (en) | Methods and kits for identifying pre-cancerous colorectal polyps and colorectal cancer | |
| CN113897434A (zh) | 鉴定肝癌状态的方法和试剂盒 | |
| CN113234820A (zh) | 鉴定前列腺癌状态的方法和试剂盒 | |
| CN113278692A (zh) | 鉴定肺结节状态的方法和试剂盒 | |
| BR112020012280A2 (pt) | composições e métodos para diagnosticar cânceres de pulmão usando perfis de expressão de gene | |
| CN114438208A (zh) | 通过外泌体miRNA生物标志物进行肺癌诊断的检测试剂盒和方法 | |
| JP5009289B2 (ja) | Ｍａｌｔリンパ腫の検査方法及びキット | |
| CN112585282A (zh) | 鉴定乳腺癌状态的方法和试剂盒 | |
| JP2011097833A (ja) | 特定の遺伝子のメチル化の頻度を、頭頸部腫瘍のバイオマーカーとして使用する方法 | |
| CN113999907A (zh) | 鉴定甲状腺癌状态的方法和试剂盒 | |
| JP6103866B2 (ja) | 大腸ガン検出方法、診断用キット及びｄｎａチップ | |
| CN118240939A (zh) | 一种结直肠癌诊断试剂盒、方法及其装置 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210330 |
|
| RJ01 | Rejection of invention patent application after publication |